Alkem Laboratories Share Price

Alkem Lab

CMP as on 24-May-22 15:44

₹ 2,931.15
-55.15 -1.85%

Open

₹ 2,999.00

Turnover (lac)

₹ 3,581

Prev. Close

₹ 2,986.30

Day's Vol (shares)

₹ 1,22,184

Day's Range (₹)

₹ 2,909.65
₹ 2,999.00

CMP as on24-May-22 15:29

₹ 2,945.85
-39.2 -1.31%

Open

₹ 2,991.25

Turnover (lac)

₹ 96

Prev. Close

₹ 2,985.05

Day's Vol (shares)

₹ 2,114

Day's Range

₹ 2,913.00
₹ 2,991.25

CMP as on 24-May-22 0:00

₹ 2,934.90
-66.05 -2.2%

Open

₹ 2,960.45

Open Interest(Contracts)

₹ 1,36,800

VWAP

₹ 2,938.14

Day's Vol (shares)

₹ 1,99,800

Day's Range (Ex.Dt. 26 May 2022)

₹ 2,906.05
₹ 2,968.55

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 28-Apr-2022 - -
Audited Results & Final Dividend Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2022 ,inter alia, to consider and approve (i) to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2022; and (ii) to consider and recommend Final Dividend, if any, for the Financial Year ended 31st March, 2022. Kindly take note of the same. The Board of Directors at its meeting held today i.e. 13th May, 2022, has, inter alia: 1. recommended a final dividend of Rs. 4/- per equity share of Rs. 2/- each for the financial year ended 31st March, 2022, for the approval of the shareholders of the Company at the ensuing Annual General Meeting. 2. fixed that the 48th Annual General Meeting of the Company shall be held on 25th August, 2022 and the cut-off date for the purpose of the said Annual General Meeting has been fixed as 18th August, 2022. 3. fixed 10th August, 2022 as the record date for the purpose of payment of final dividend. The dividend, if declared by the shareholders, shall be paid on and from 30th August, 2022. Kindly take the same on record. Please find enclosed the outcome of the BM dated 13.5.22 In continuation of our letter dated 28th April, 2022 and pursuant to Regulation 30 read with Regulation 33 of the SEBI LODR (Listing Regulations) the Board of Directors of the Company, at its meeting held today, i.e. 13th May, 2022, has inter alia approved the Standalone and Consolidated Audited Financial Results for the quarter and financial year ended 31st March, 2022. Accordingly, we are enclosing herewith Standalone and Consolidated Audited Financial Results for the quarter and financial year ended 31st March, 2022 and the Auditors Report thereon. The Company hereby declares that the Auditors have expressed an unmodified opinion in the Audit Reports on Standalone and Consolidated Financial Results for the quarter and financial year ended 31st March, 2022. The meeting of the Board of Directors of the Company commenced at 11.00 A.M and concluded at 1.30 P.M. Kindly take the same on record. Approved the appointment of M/s RSM & Co., Company Secretaries, as Secretarial Auditor of the Company for the financial year 2022-23. The Board of Directors at its meeting held today i.e. 13th May, 2022, has, inter alia: 1. recommended a final dividend of Rs. 4/- per equity share of Rs. 2/- each for the financial year ended 31st March, 2022, for the approval of the shareholders of the Company at the ensuing Annual General Meeting. 2. fixed that the 48th Annual General Meeting of the Company shall be held on 25th August, 2022 and the cut-off date for the purpose of the said Annual General Meeting has been fixed as 18th August, 2022. 3. fixed 10th August, 2022 as the record date for the purpose of payment of final dividend. The dividend, if declared by the shareholders, shall be paid on and from 30th August, 2022. Kindly take the same on record. (As Per BSE Announcement Dated on 13.05.2022)
Board Meeting - 24-Jan-2022 - -
Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2022 inter alia to consider and approve (i) the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31st December 2021; and (ii) Interim Dividend for the Financial Year 2021-2022. The record date for the purpose of payment of Interim Dividend for the Financial Year 2021-2022 would be Saturday 12th February 2022 subject to declaration of the said Interim Dividend by the Board of Directors in its meeting to be held on 04th February 2022. Kindly take note of the same. The Board of Directors of the Company, at its meeting held today, i.e. 04th February, 2022 have inter alia: a. Approved the Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended 31st December, 2021. b. Declared Interim Dividend of Rs 30/- (Rupees Thirty only) per equity share on the face value of Rs. 2/- per share for the financial year 2021-22 pursuant to Regulation 43 read with Regulation 30 of the Listing Regulations. The meeting of the Board of Directors of the Company commenced at 10.30 a.m. and concluded at 01.00 p.m. Kindly take the same on record. (As Per BSE Announcement Dated on 04.02.2022)
Board Meeting - 20-Dec-2021 - -
We wish to inform you that the Board of Directors (Board) of Alkem Laboratories Limited (the Company), at its meeting held today, i.e. on 20th December, 2021 has appointed Mrs. Madhurima Singh (DIN: 09137323) as an Additional Director and Whole Time Director designated as Executive Director on the Board for a period of five years, with effect from 20th December, 2021, subject to the approval of the shareholders of the Company. Necessary particulars in relation to the said appointment, are included in Annexure I. Kindly take the same on your records. This is to inform you that pursuant to the provisions of Section 110 and other applicable provisions, if any, of the Companies Act, 2013 read with Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014, the Board of Directors at its meeting held today i.e. 20th December, 2021 has decided to seek approval of the shareholders by way of postal ballot (voting by electronic means) for appointment of Mrs. Madhurima Singh (DIN: 09137323) as a Whole Time Director designated as Executive Director for a period of five consecutive years w.e.f 20th December, 2021. The Company has fixed 31st December, 2021 as cut-off date for ascertaining the eligibility of shareholders for dispatch of Postal Ballot Notice and voting through electronic means. Kindly take note of the same.
Board Meeting - 02-Nov-2021 - -
Quarterly Results The Board of Directors at its meeting held today i.e. 12th November, 2021, has approved the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2021. Accordingly, we are enclosing herewith Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2021 and the Limited Review Report of the Statutory Auditors of the Company. The meeting of the Board of Directors of the Company commenced at 10 am and concluded at 12.30 pm. In continuation of our letter dated 02nd November, 2021 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we are enclosing the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2021, duly approved by the Board of Directors of the Company, at its meeting held today, i.e. 12th November, 2021. The meeting of the Board of Directors of the Company commenced at 10.00 A.M and concluded at 12.30 P.M. A copy of the Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Listing Regulations, is also enclosed herewith. Kindly take the same on record. (As per BSE Announcement Dated on 12/11/2021)
Board Meeting - 26-Jul-2021 - -
Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2021 ,inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2021. Kindly take note of the same. The Board of Directors at its meeting held today i.e. 06th August, 2021, has approved the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30th June, 2021. Accordingly, we are enclosing herewith Standalone and Consolidated Unaudited Financial Results for the quarter ended 30th June, 2021 and the Limited Review Report of the Statutory Auditors of the Company. The meeting of the Board of Directors of the Company commenced at 11 am and ended at 1. 30 pm. In continuation of our letter dated 26th July, 2021 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we are enclosing the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30th June, 2021, duly approved by the Board of Directors of the Company, at its meeting held today, i.e. 06th August, 2021. The meeting of the Board of Directors of the Company commenced at 11.00 A.M and concluded at 1.30 P.M. A copy of the Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Listing Regulations, is also enclosed herewith. Kindly take the same on record. (As Per BSE Announcement Dated on 06.08.2021)
Board Meeting - 14-May-2021 - -
Alkem Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on May 25, 2021, inter alia:1. To consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2021; and2. To consider and recommend Final Dividend, if any, for the Financial Year ended March 31, 2021. The BOD at its meeting held today i.e. 25.05.21 has, inter alia approved the Standalone and Consolidated Audited Financial Statements for the quarter and FY ended 31.3.21 and other items as enclosed herewith. continuation of our letter dated 14th May, 2021 and pursuant to Regulation 30 read with Regulation 33 of the SEBI LODR (Listing Regulations) the Board of Directors of the Company, at its meeting held today, i.e. 25th May, 2021, has inter alia: . 1. Approved the Standalone and Consolidated Audited Financial Results for the quarter and financial year ended 31st March, 2021. Accordingly, we are enclosing herewith Standalone and Consolidated Audited Financial Results for the quarter and financial year ended 31st March, 2021 and the Auditors Report thereon. The Company hereby declares that the Auditors have expressed an unmodified opinion in the Audit Reports on Standalone and Consolidated Financial Results for the quarter and financial year ended 31st March, 2021. The meeting of the Board of Directors of the Company commenced at 11.00 A.M and concluded at 1.45 P.M Kindly take the same on record. Alkem Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 25, 2021, inter alia, has recommended a final dividend of Rs. 5/- (Rupees Five only) per equity share of Rs. 2/- each for the financial year ended March 31, 2021, for the approval of the shareholders of the Company at the ensuing Annual General Meeting. The Board of Directors at its meeting held today i.e. 25th May, 2021, has, inter alia: 1. recommended a final dividend of Rs. 5/- (Rupees Five only) per equity share of Rs. 2/- each for the financial year ended 31st March, 2021, for the approval of the shareholders of the Company at the ensuing Annual General Meeting. 2. fixed that the 47th Annual General Meeting of the Company shall be held on 27th August, 2021 and the record date for the purpose of the said Annual General Meeting has been fixed as 20th August, 2021. 3. fixed 10th August, 2021 as the record date for the purpose of payment of final dividend. The dividend, if declared by the shareholders, shall be paid on and from 01st September 2021. Kindly take the same on record. (As Per BSE Announcement Dated 25.05.2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity